Auspex Pharmaceuticals Inc (NASDAQ:ASPX) Reports Positive Interim Analysis in Huntington’s Disease Treatment

Auspex Pharmaceuticals Inc (NASDAQ:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, announced largely positive early results from a pre-specified interim subgroup analysis of the ongoing open-label ARC-HD Switch study from tetrabenazine to SD-809.

The interim analysis was conducted to determine whether chorea control was maintained after converting subjects with Huntington’s disease (HD) from stable doses of tetrabenazine to SD-809, which is administered in lower doses and with a simplified dosing regimen.

The conversion to SD-809 was generally well tolerated as no subject prematurely discontinued from the study, there were no adverse events of loss of chorea control and no serious adverse events were reported.

“These data suggest that SD-809 is biologically active in these Huntington’s disease patients and that switching to SD-809 was generally well tolerated,” said David Stamler, M.D., chief medical officer. “The data give us confidence to complete the ongoing trials in HD as planned and to accelerate the development of SD-809 in other hyperkinetic movement disorders such as tardive dyskinesia and Tourette syndrome.”

ASPX fell nearly 7% in regular trading and is lightly traded in after-hours action. It moves in a 52-week range of $13.25 to $35.78.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>